Posted by Michael Wonder on 31 Mar 2021
Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy
30 March 2021 - Roche is actively engaging with health authorities in the European Union to achieve broad and rapid access for people with spinal muscular atrophy.
Roche today announced that the European Commission has approved Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
